According to Innoviva's latest financial reports the company has a price-to-book ratio of 1.55.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2022-12-31 | 1.63 | -28.3% |
2021-12-31 | 2.28 | 10.28% |
2020-12-31 | 2.07 | -50.7% |
2019-12-31 | 4.19 | -62.2% |
2018-12-31 | 11.1 | -286.18% |
2017-12-31 | -5.96 | 81.25% |
2016-12-31 | -3.29 | -6.91% |
2015-12-31 | -3.53 | -52.08% |
2014-12-31 | -7.37 | -155.44% |
2013-12-31 | 13.3 | -14.04% |
2012-12-31 | 15.5 | -164.43% |
2011-12-31 | -24.0 | -73.29% |
2010-12-31 | -89.8 | 1922.72% |
2009-12-31 | -4.44 | -7.98% |
2008-12-31 | -4.83 | -73.15% |
2007-12-31 | -18.0 | -161.25% |
2006-12-31 | 29.3 | 74.59% |
2005-12-31 | 16.8 | 237.79% |
2004-12-31 | 4.98 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
![]() OPKO Health
OPK | 0.7553 | -51.32% | ๐บ๐ธ USA |
![]() Onconova Therapeutics ONTX | 0.7993 | -48.48% | ๐บ๐ธ USA |